Venous Thromboembolism (VTE) Treatment Market Size, Segmentation, Opportunities, Trends, Growth and Industry Forecast To 2022

Venous Thromboembolism (VTE) Treatment Market

According to Cleveland Clinic, venous thromboembolism (VTE) is a disease that includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). It is a common, lethal disorder that affects hospitalized and non-hospitalized patients, recurs frequently, is often overlooked, and results in long-term complications, including chronic thromboembolic pulmonary hypertension (CTPH) and post-thrombotic syndrome (PTS). An inclusive scientific review by the WTD steering committee revealed that 10 million cases of VTE occur annually – across low, middle, and high-income countries. In addition, up to 60% of VTE cases occur during or after hospitalization, making it a leading preventable cause of hospital death. The venous thromboembolism treatment market can be segmented into diseases such as deep venous thrombosis (DVT) and pulmonary embolism (PE). The venous thromboembolism treatment market is segmented based on drugs such as heparin, apixaban, dabigatran, rivaroxaban, edoxaban, and warfarin. The therapy market for VTE treatment comprises compression therapy and thrombolytic therapy.

The key drivers assisting the overall market growth of venous thromboembolism treatment are increasing prevalence and incidence rate of venous thromboembolism, and high awareness related to existing treatments for venous thromboembolism are driving the global venous thromboembolism treatment market. In addition, factors such as stringent regulatory approvals and challenges in adapting newer drugs and therapies in the market are restraining the growth of this market. North America is the leading regional market for venous thromboembolism treatments. Europe trails it due to a large population suffering from venous thromboembolic in these regions. The key factors driving North America and Europe’s venous thromboembolism market are high healthcare expenditure, developed healthcare infrastructure, and high awareness of the disease and available treatments.

The global venous thromboembolism treatment market is segmented on the following bases:

Type of Disease

  • Deep Venous Thrombosis
  • Pulmonary Embolism

Type of Treatment

  • Therapeutics
  • Heparin
  • Apixaban
  •  Dabigatran
  • Rivaroxaban
  • Edoxaban
  • Warfarin

Other Treatments

  • Compression Therapy
  • Inferior Vena Cava Filter
  • Thrombolytic Therapy


  • North America
  • US
  • Canada
  • Europe
  • UK
  • Germany
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Rest of APAC
  • Latin America
  • Middle East and Africa

Key Players Identified for Venous Thromboembolism Treatment Market Include but are Not Limited to:

Abbott Laboratories, Merck & Co., Sanofi S.A., Dupont Pharm Co, Boehringer Ingelheim GmbH, Upsher-Smith Laboratories, Inc., Wockhardt Ltd, Bayer AG, Bristol-Myers Squibb Company, 3M Health Care, ArjoHuntleigh, BSN medical, Medtronic plc, Bio Compression Systems, Inc., and Pfizer Inc. and others.

This report offers:

  • An overview of the global markets for venous thromboembolism treatment
  • Market trends assessment for the period 2014-2022, with historical information for 2014 & 2015 and projections through 2022, with respective CAGRS during 2016-2022
  • Qualitative assessment tools such as market drivers, challenges, and opportunities
  • Market competition scrutiny tools such as market share analysis, fractal map assessment, Porter’s Five Forces model
  • Focus on each level of market segmentation based on product approvals, launches, and current and anticipated market dynamics.
  • A general overview of the industry structure
  • Company profiles highlighting key information about the major players operating in the venous thromboembolism treatment market

Frequently Asked Questions:

The market for Venous Thromboembolism (VTE) Treatment is expected to reach US$ XX Bn in 2022.

The Venous Thromboembolism (VTE) Treatment Market is expected to see significant CAGR growth over the coming years, at XX %.

The report is forecasted from 2016-2022.

The base year of this report is 2021.

Choose License Type
Trusted By
Published Date:  May 2016
Category:  Medical Devices
Report ID:   57849
Report Format:   PDF
Pages:   120
Rating:    4.4 (50)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support